Document Detail


A soluble form of fibroblast growth factor receptor 2 (FGFR2) with S252W mutation acts as an efficient inhibitor for the enhanced osteoblastic differentiation caused by FGFR2 activation in Apert syndrome.
MedLine Citation:
PMID:  15310757     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Apert syndrome is an autosomal dominant disease characterized by craniosynostosis and bony syndactyly associated with point mutations (S252W and P253R) in the fibroblast growth factor receptor (FGFR) 2 that cause FGFR2 activation. Here we investigated the role of the S252W mutation of FGFR2 on osteoblastic differentiation. Osteoblastic cells derived from digital bone in two Apert patients with the S252W mutation showed more prominent alkaline phosphatase activity, osteocalcin and osteopontin mRNA expression, and mineralized nodule formation compared with the control osteoblastic cells derived from two independent non-syndromic polydactyly patients. Stable clones of the human MG63 osteosarcoma cells (MG63-Ap and MG63-IIIc) overexpressing a splice variant form of FGFR2 with or without the S252W mutation (FGFR2IIIcS252W and FGFR2IIIc) showed a higher RUNX2 mRNA expression than parental MG63 cells. Furthermore MG63-Ap exhibited a higher osteopontin mRNA expression than did MG63-IIIc. The enhanced osteoblastic marker gene expression and mineralized nodule formation of the MG63-Ap was inhibited by the conditioned medium from the COS-1 cells overexpressing the soluble FGFR2IIIcS252W. Furthermore the FGF2-induced osteogenic response in the mouse calvarial organ culture system was blocked by the soluble FGFR2IIIcS252W. These results show that the S252W mutation in the FGFR2 gene enhances the osteoblast phenotype in human osteoblasts and that a soluble FGFR2 with the S252W mutation controls osteoblast differentiation induced by the S252W mutation through a dominant negative effect on FGFR2 signaling in Apert syndrome.
Authors:
Yukiho Tanimoto; Masahiko Yokozeki; Kenji Hiura; Kazuya Matsumoto; Hideki Nakanishi; Toshio Matsumoto; Pierre J Marie; Keiji Moriyama
Related Documents :
12416537 - Tgf-beta1, tgf-beta2, tgf-beta3 and msx2 expression is elevated during frontonasal sutu...
18539107 - Differential modulation of rankl isoforms by human osteoarthritic subchondral bone oste...
8187167 - Carbonic anhydrase ii gene transcript in cultured osteoclasts from neonatal rats: effec...
11454517 - Serum parathyroid hormone, but not menopausal status, is associated with the expression...
12098517 - A non-peptide substance p antagonist down-regulates sp mrna expression in human mononuc...
11899077 - Role of the nf-kappab pathway in the pathogenesis of human disease states.
Publication Detail:
Type:  Journal Article     Date:  2004-08-13
Journal Detail:
Title:  The Journal of biological chemistry     Volume:  279     ISSN:  0021-9258     ISO Abbreviation:  J. Biol. Chem.     Publication Date:  2004 Oct 
Date Detail:
Created Date:  2004-10-25     Completed Date:  2004-11-30     Revised Date:  2012-06-05    
Medline Journal Info:
Nlm Unique ID:  2985121R     Medline TA:  J Biol Chem     Country:  United States    
Other Details:
Languages:  eng     Pagination:  45926-34     Citation Subset:  IM    
Affiliation:
Department of Orthodontics and Dentofacial Orthopedics, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8504, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acrocephalosyndactylia / genetics*
Animals
COS Cells
Cell Differentiation
Child, Preschool
Female
Fibroblast Growth Factor 2 / pharmacology
Humans
Male
Osteoblasts / cytology*
Phenotype
Phosphorylation
Point Mutation*
Receptor Protein-Tyrosine Kinases / chemistry,  genetics*,  physiology
Receptor, Fibroblast Growth Factor, Type 2
Receptors, Fibroblast Growth Factor / chemistry,  genetics*,  physiology
Chemical
Reg. No./Substance:
0/Receptors, Fibroblast Growth Factor; 103107-01-3/Fibroblast Growth Factor 2; EC 2.7.10.1/FGFR2 protein, human; EC 2.7.10.1/Receptor Protein-Tyrosine Kinases; EC 2.7.10.1/Receptor, Fibroblast Growth Factor, Type 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of the histone acetyl transferase Tip60 in the p53 pathway.
Next Document:  Tax deregulation of NF-kappaB2 p100 processing involves both beta-TrCP-dependent and -independent me...